Does Blue Cross Blue Shield of Michigan Cover Viagra?

The direct answer

There is no publicly available BCBSM formulary excerpt in the source material behind this article, so this page cannot tell you with certainty which tier your specific BCBSM plan places sildenafil or Viagra on, whether prior authorization applies, or what your copay will be. BCBSM offers many distinct plan designs (commercial PPO, HMO, self-funded employer plans it administers, and Medicare Advantage), and formularies differ across them and change over time.

What is well established, independent of any one insurer, is the general market pattern behind why insurers treat these two products differently, and the federal rules that apply regardless of which insurer you have. The rest of this article separates those stable facts from the plan-specific details you need to confirm directly.

Why generic sildenafil and brand Viagra are usually treated differently

Pfizer's exclusivity on sildenafil citrate (Viagra) ended, and the FDA has since approved multiple generic manufacturers to market the same active compound at the same approved doses (25 mg, 50 mg, 100 mg). You can check current generic approval status for any drug, including sildenafil, in the FDA's Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations).

The FDA requires a generic drug to demonstrate bioequivalence to the reference product, meaning it delivers the same amount of active ingredient into the bloodstream over the same timeframe as the brand (FDA, Generic Drug Facts). Some reviews have reported comparable efficacy and safety between generic sildenafil and brand Viagra, though this article does not have a verified source to cite for that specific finding.

Because a generic is chemically and clinically equivalent but typically far cheaper to acquire, most commercial insurers place generics at their lowest-cost tier and place the corresponding brand at a higher, non-preferred tier or exclude it outright unless a brand is medically necessary. This is standard formulary economics, not something unique to BCBSM. Whether your BCBSM plan follows that general pattern for sildenafil and Viagra specifically is something only your plan's current formulary can confirm.

If your prescriber writes for brand-name Viagra with "dispense as written," most insurers either deny the claim or apply a much higher cost-sharing tier. Getting the brand covered generally requires a formulary exception request with clinical justification for why the generic is not appropriate; these requests are approved infrequently for PDE5 inhibitors because the clinical difference between brand and generic sildenafil is minimal. If cost matters to you, ask your prescriber to write for "sildenafil" without a brand-only instruction, which allows the pharmacy to dispense the generic.

What guidelines say about first-line ED treatment

The American Urological Association's 2018 erectile dysfunction guideline lists PDE5 inhibitors, including sildenafil, tadalafil, vardenafil, and avanafil, as effective first-line pharmacotherapy for ED, without recommending one agent over another on efficacy grounds (Burnett et al., 2018, AUA Guideline). Because the guideline does not favor a specific PDE5 inhibitor, insurers generally have latitude to prefer whichever agent costs them least, which is usually generic sildenafil or generic tadalafil.

A meta-analysis of PDE5 inhibitor trials found no statistically significant efficacy differences between sildenafil, tadalafil, vardenafil, and avanafil when compared head-to-head, with the main practical differences being onset time and duration of action (Yuan et al., 2013, European Urology). Tadalafil's effect can last up to roughly 36 hours, compared with roughly 4 to 6 hours for sildenafil, and tadalafil is also available as a low daily dose for continuous use (Brock et al., 2002).

Prior authorization, quantity limits, and step therapy: what to actually check

Many commercial insurers, including plans administered by BCBSM, apply quantity limits to ED medications (commonly somewhere in a 6-to-12-tablet-per-month range across the industry) and may or may not require prior authorization depending on the specific plan and whether it is fully insured or a self-funded employer plan. Self-funded employer groups can set their own utilization management rules even when BCBSM administers the plan, which is one reason coverage can differ between two people who both say they "have BCBS of Michigan."

Verification checklist: what's stable vs. what you must reverify

Stable facts that don't depend on your insurer or the date you're reading this:

• Sildenafil citrate is FDA-approved for erectile dysfunction (as Viagra and as generic sildenafil) at 25 mg, 50 mg, and 100 mg doses, and separately as Revatio (20 mg) for pulmonary arterial hypertension, these are different approved indications under different brand names
• FDA-approved generics must meet bioequivalence standards to the reference drug (FDA, Generic Drug Facts)
• Current generic manufacturers and approval status for sildenafil can be checked any time in the FDA Orange Book
• AUA guidelines list sildenafil, tadalafil, vardenafil, and avanafil as first-line ED pharmacotherapy with no stated efficacy preference among them (AUA guideline)
• Medicare Part D has historically excluded drugs prescribed for the treatment of erectile dysfunction under its statutory exclusions

Date-sensitive facts you must confirm directly with BCBSM, not from this article:

• Which tier your specific BCBSM plan (commercial, self-funded employer, or Medicare Advantage) places generic sildenafil and brand Viagra on
• Whether prior authorization is required for your plan
• The exact quantity limit per fill for your plan
• Whether step therapy requires trying sildenafil before tadalafil is covered at a preferred tier
• Your actual copay or coinsurance amount, and whether your deductible has been met
• Whether your Medicare Advantage plan offers any supplemental ED drug benefit, and what it covers
• Current cash and discount-card prices at a specific Michigan pharmacy, since these change frequently and are not set by BCBSM

How to check: log into the BCBSM member portal and search the formulary, call the member services number on the back of your insurance card, review your plan's Summary of Benefits and Coverage document, or ask your pharmacist to run a test claim, which will surface any prior authorization block or quantity limit denial in real time before you pay.

Medicare Part D and Medicare Advantage

Medicare Part D has historically excluded coverage of drugs used specifically for erectile dysfunction as a category, under long-standing statutory exclusions for the Part D benefit. This is a federal program rule that applies across Part D plans generally, not a choice specific to BCBSM.

Some Medicare Advantage plans, including some administered by BCBSM, offer supplemental drug benefits beyond the standard Part D formulary. Whether a given BCBSM Medicare Advantage plan includes any ED medication as a supplemental benefit, and under what limits, has to be checked in that plan's current Evidence of Coverage or supplemental formulary; it is not something this article can state as a fixed rule.

Sildenafil sold as Revatio (20 mg) for pulmonary arterial hypertension is a distinct FDA-approved indication from ED, and Part D plans generally process PAH claims for it under standard formulary rules tied to the PAH diagnosis rather than the ED exclusion (Galiè et al., 2005, sildenafil for pulmonary arterial hypertension).

What you might actually pay

Out-of-pocket cost for any prescription depends on your plan's tier placement for that specific drug, whether you've met your deductible, your copay or coinsurance structure, and which pharmacy you use. Because this article does not have a BCBSM price sheet to cite, it cannot give you a reliable dollar figure for your plan. Insurer-negotiated rates and cash/discount prices both change over time and by pharmacy, so treat any specific number you see elsewhere, including on prior versions of pages like this one, as something to reverify rather than rely on.

One study in JAMA Network Open examined out-of-pocket spending on PDE5 inhibitors across different insurance plans and found substantial variation by plan (Patel et al., 2022). The exact size of that variation and the specific dollar ranges reported in that study should be confirmed by reading the paper directly before citing a specific figure to a reader; this article is not treating any single number from it as verified.

If your BCBSM plan excludes ED medications entirely or you have not met a high deductible, a pharmacy discount program or cash price may cost less than your insurance rate for that fill, though a cash purchase generally does not count toward your deductible. Compare your plan's contracted rate (ask your pharmacist to run both a covered and cash-price version of the claim) before deciding which to use.

Alternatives if sildenafil doesn't work or isn't covered

If sildenafil is not effective or not covered on acceptable terms, other FDA-approved oral options exist, and insurers generally cover at least one at a preferred tier:

• Tadalafil (Cialis), available generically, with a longer duration of action and a low-dose daily option
• Vardenafil, available generically
• Avanafil (Stendra), which remains brand-only and is typically priced and tiered higher

For men who do not respond to oral PDE5 inhibitors, second-line options include alprostadil delivered by injection (Caverject, Edex) or as an intraurethral suppository (MUSE). These typically require documentation that oral therapy was tried and failed, or is contraindicated, before an insurer will authorize them.

If cost or coverage remains a barrier, discuss it directly with your prescriber rather than adjusting your own dose or splitting tablets without their guidance; they can advise on clinically appropriate options and help navigate a formulary exception or appeal if one is warranted.

If BCBSM denies your claim

If a sildenafil or Viagra claim is denied, request the denial letter, which will state the specific reason (commonly a quantity limit, a brand-over-generic request, or missing diagnosis documentation). Your prescriber can then submit a prior authorization request or appeal addressing that specific reason.

Insurance appeal timelines and the availability of an external review through Michigan's Department of Insurance and Financial Services (DIFS) are set by state and federal rules that can change and that this article does not have a verified, current citation for. Confirm the exact deadlines and process from your denial letter or by contacting BCBSM and DIFS directly rather than relying on a specific number of days quoted in an article.